Idiopathic pulmonary fibrosis

Pathophysiology - Scarred for Life

• Hallmark: Biopsy reveals Usual Interstitial Pneumonia (UIP), a pattern of progressive fibrosis.
• Mechanism: Begins with repetitive, microscopic injury to alveolar epithelial cells, leading to aberrant wound healing.
• Key Mediators: Involves pro-fibrotic cytokines, primarily TGF-β1, which stimulates fibroblast proliferation and excessive extracellular matrix (collagen) deposition.

⭐ Classic finding is spatial & temporal heterogeneity: patches of late-stage honeycomb fibrosis alternate with less affected or normal lung tissue.

Clinical Presentation & Diagnosis - Can't Catch a Breath

• Presentation: Insidious onset of dyspnea on exertion (DOE) and a persistent dry cough, typically for > 6 months.
• On Examination:
  • Fine, bibasilar inspiratory crackles ("Velcro-like" rales).
  • Digital clubbing is present in up to 50% of cases.
• Pulmonary Function Tests (PFTs):
  • Classic restrictive pattern: ↓ FVC, ↓ TLC, with a normal or ↑ FEV1/FVC ratio.
  • Markedly ↓ DLCO (diffusing capacity for carbon monoxide).
• High-Resolution CT (HRCT):
  • The key diagnostic modality, often sufficient for diagnosis.
  • Shows a "Usual Interstitial Pneumonia" (UIP) pattern:
    • Honeycombing (clustered cystic airspaces).
    • Traction bronchiectasis.
    • Reticular opacities with a subpleural, bibasilar predominance.

⭐ The combination of bibasilar "Velcro-like" crackles and digital clubbing in a patient > 60 years old is highly suggestive of IPF.

Radiology & Histopathology - Honeycomb Lungs

• High-Resolution CT (HRCT): Primary imaging modality.

  • Hallmark: Honeycombing (clustered, thick-walled cystic airspaces).
  • Distribution: Predominantly bibasilar and subpleural.
  • Other findings: Reticular opacities, traction bronchiectasis, minimal ground-glass opacities.

• Histopathology (Biopsy): Shows Usual Interstitial Pneumonia (UIP) pattern.

  • Key Feature: Temporal heterogeneity (alternating areas of normal lung, inflammation, and dense fibrosis).
  • Microscopic hallmark: Fibroblastic foci (collections of active fibroblasts).

⭐ Exam Favorite: A "definite UIP" pattern on HRCT (bibasilar, subpleural honeycombing) is so specific that a surgical lung biopsy is often not required for diagnosis in the right clinical context.

Management & Prognosis - Slowing the Scarring

• Antifibrotic Therapy: Goal is to slow Forced Vital Capacity (FVC) decline.
  • Pirfenidone: Inhibits TGF-β, a key mediator of fibrosis.
  • Nintedanib: A tyrosine kinase inhibitor targeting pro-fibrotic pathways (VEGFR, FGFR, PDGFR).
• Supportive & Symptomatic Care:
  • Supplemental O₂ for hypoxemia (maintain SaO₂ >88%).
  • Pulmonary rehabilitation to improve dyspnea and quality of life.
  • Vaccinations (influenza, pneumococcus).
• Definitive Treatment:
  • Lung transplantation is the only curative option for eligible candidates.
• Prognosis:
  • Median survival is 3-5 years post-diagnosis.

⭐ Acute exacerbations of IPF are a major cause of mortality, with in-hospital mortality rates often exceeding 50%.

High‑Yield Points - ⚡ Biggest Takeaways

• Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrosing interstitial pneumonia, mainly in males >60.
• Presents with gradual dyspnea on exertion and a persistent non-productive cough.
• Classic physical finding: bibasilar inspiratory "Velcro-like" crackles.
• HRCT is key for diagnosis, showing a UIP pattern with bibasilar, subpleural honeycombing.
• PFTs show a restrictive pattern (↓ FVC, normal/↑ FEV1/FVC ratio) and severely ↓ DLCO.
• Pirfenidone and nintedanib slow disease progression; lung transplant is the only definitive cure.